INNOVIVE Pharmaceuticals Presents Preliminary Data at ASH Showing INNO-305 Elicits Immune Response in Patients with Myeloid and Thoracic Neoplasms

ATLANTA--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today presented results from a pilot study examining INNO-305, a Wilms Tumor Protein (WT1) heteroclitic peptide immunotherapeutic vaccine, in patients with myeloid and thoracic neoplasms. Preliminary data from the pilot study suggests repeat administration with INNO-305 is well tolerated and immune response can be elicited following three vaccinations. The data were presented at the 49th American Society of Hematology (ASH) Annual Meeting in Atlanta.

“We believe INNO-305 has the potential to elicit robust immune responses in patients with several serious cancer types including AML, CML, myelodysplastic syndrome, non small cell lung cancer and mesothelioma.”

Date:	Saturday, December 8, 2007 from 5:30 pm to 7:30 pm ET
Session Type:	Poster Presentation Hall B4, Board #57-I
Abstract:	# 903
Title:	"Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic
	Peptide Vaccine in Patients with Myeloid and Thoracic
	Neoplasms."

WT1 peptide cancer immunotherapeutics target the WT1 transcription factor, which is over-expressed in hematologic cancers. INNO-305, composed of four WT-1 peptides, is unique due to its ability to stimulate both CD8 and CD4 T-cells, which may result in a more robust and ubiquitous immune response. In the study conducted at the Memorial Sloan-Kettering Cancer Center, patients receive six vaccinations over 12 weeks with INNO-305 along with the immune adjuvant Montanide. Preliminary data indicates that a CD4 response was seen in five of six patients and a CD8 response was seen in patients with HLA-A0201.

“Sloan-Kettering Cancer Center’s pilot study of INNO-305 provides important preliminary data that supports ongoing development of INN0-305,” stated Steve Kelly, President and CEO of INNOVIVE Pharmaceuticals. “We believe INNO-305 has the potential to elicit robust immune responses in patients with several serious cancer types including AML, CML, myelodysplastic syndrome, non small cell lung cancer and mesothelioma.”

About INNO-305

INNO-305, also known as WT1 heteroclitic peptide immunotherapy, is in a Phase I clinical trial for the treatment of patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) as well as patients with non-small cell lung cancer (NSCLC) and mesothelioma. INNO-305 is unique among WT1 peptide cancer immunotherapeutics because of its ability to stimulate both CD8 and CD4 T-cells. It is believed that stimulating both types of T-cells may result in a more robust and ubiquitous immune response.

About INNOVIVE Pharmaceuticals

INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information please visit www.innovivepharma.com.

Forward-looking Statements

This material contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These include statements concerning plans, objectives, goals, strategies, future events or performance and all other statements which are other than statements of historical fact, including without limitation, statements containing words such as "believes," "anticipates," "expects," "estimates," "projects," "will," "may," "might" and words of a similar nature. Such statements involve risks and uncertainties that could cause actual results to differ materially from those projected. All forward looking statements assume the Company is able to immediately obtain additional working capital; without such additional working capital, the Company will not be able to sustain its operations or conduct its business. Among other things, there can be no assurances that any of INNOVIVE’s development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include INNOVIVE’s immediate need for operating capital, the risk that the results of clinical trials may not support INNOVIVE’s claims, the possibility of being unable to obtain regulatory approval of INNOVIVE’s product candidates, INNOVIVE’s reliance on third party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. These and other risks are discussed in INNOVIVE’S periodic reports filed with the SEC. The forward-looking statements contained herein represent the judgment of INNOVIVE as of the date this material was drafted. INNOVIVE disclaims, however, any intent or obligation to update any forward-looking statements.